Top Page
Bioxyne Limited
(Sydney:BXN)
Bioxyne Limited (BXN) vs. iShares MSCI Australia ETF (EWA)
Bioxyne Limited Business Overview & Revenue Model
Bioxyne Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.42M | 30.42M | 9.33M | 5.16M | 463.64K | 2.11M |
| Gross Profit | 10.45M | 10.45M | 3.40M | 343.13K | -224.10K | 639.71K |
| EBITDA | 5.34M | 5.34M | -13.03M | -1.88M | -463.30K | -425.93K |
| Net Income | 4.90M | 4.90M | -13.33M | -1.94M | -494.02K | -495.73K |
Balance Sheet | ||||||
| Total Assets | 20.90M | 20.90M | 6.70M | 17.69M | 445.59K | 2.68M |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 7.67M | 1.03M | 3.85M | 65.93K | 1.60M |
| Total Debt | 1.53M | 1.53M | 673.72K | 558.61K | 397.39K | 47.46K |
| Total Liabilities | 9.53M | 9.53M | 3.40M | 2.69M | 810.43K | 744.75K |
| Stockholders Equity | 11.68M | 11.68M | 3.61M | 15.14M | -364.84K | 1.88M |
Cash Flow | ||||||
| Free Cash Flow | 3.86M | 3.86M | -4.05M | -897.92K | -566.88K | 19.47K |
| Operating Cash Flow | 6.28M | 6.28M | -3.56M | -841.28K | -506.81K | 53.13K |
| Investing Cash Flow | -2.07M | -2.41M | -492.66K | 4.10M | 26.61K | -33.66K |
| Financing Cash Flow | 2.42M | 2.76M | 1.21M | 805.36K | 493.24K | -46.78K |
Bioxyne Limited Technical Analysis
Bioxyne Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$108.55M | 15.48 | 10.07% | 2.61% | 38.25% | 361.54% | |
| ― | AU$91.22M | 17.50 | 61.21% | ― | 204.87% | ― | |
| ― | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
| ― | AU$27.27M | -1.37 | -31.14% | ― | -15.07% | 29.50% | |
| ― | AU$26.13M | 33.91 | ― | ― | 6.76% | ― | |
| ― | €16.79M | -0.47 | -184.71% | ― | 39.53% | 49.99% | |
| ― | AU$7.07M | ― | -60.84% | ― | -18.70% | 20.83% |
Bioxyne Limited Corporate Events
Bioxyne Limited has announced its upcoming Annual General Meeting scheduled for November 26, 2025, in Sydney. Shareholders are encouraged to lodge proxy forms and submit questions in advance. This meeting is significant for stakeholders as it reflects the company’s commitment to transparency and shareholder engagement, potentially impacting its strategic direction and market positioning.
Bioxyne Limited has announced its Annual General Meeting (AGM) scheduled for Wednesday, 26 November 2025, at Addisons in Sydney. Shareholders are encouraged to participate in the meeting, where they will have the opportunity to ask questions and vote on resolutions via a poll. The company has provided a Proxy Form for shareholders to record their votes in advance, emphasizing the importance of shareholder engagement in the decision-making process.
Bioxyne Limited has announced a change in the director’s interest notice, specifically relating to Mr. Jason Hine. The change involves the acquisition of 4,500,000 performance rights, awarded due to the achievement of performance milestones for 2023 to 2025. This adjustment in securities reflects the company’s ongoing commitment to aligning director incentives with performance targets, potentially impacting the company’s governance and stakeholder confidence.
Bioxyne Limited has announced the quotation of 18 million ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 27, 2025. This move, part of an employee incentive scheme, is expected to enhance the company’s market presence and potentially increase shareholder value by expanding its capital base.
Bioxyne Limited has announced its dual listing on the Frankfurt Stock Exchange, aiming to engage with global investors and enhance its presence in the European market. This strategic move aligns with the company’s focus on Europe, supported by a recent supply agreement and the appointment of a European Investor Relations Specialist. The dual listing is expected to increase Bioxyne’s visibility and provide greater access to European investors, particularly in Germany, where the legal cannabis market is expanding rapidly.
Recent developments in U.S. cannabis classification, specifically the potential rescheduling of cannabis to a Schedule III substance, could significantly impact the regulatory environment and investment climate for cannabinoid and psychedelic-derived therapeutics. This change may facilitate broader research access, ease banking and tax constraints, and attract institutional investment, creating momentum in the cannabis sector. Bioxyne Limited is well-positioned to benefit from these changes, potentially accelerating its growth strategy through improved capital access and reduced regulatory friction, even though the changes do not directly affect Australian regulations.
Bioxyne Limited has updated its corporate governance statement, which is now available on its website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, highlighting its commitment to transparency and accountability. This update reinforces Bioxyne’s dedication to maintaining high governance standards, potentially strengthening its position in the industry and reassuring stakeholders of its operational integrity.
Bioxyne Limited has received import authorizations from the German Government for 1,550kg of medical cannabis products, marking its entry into the German cannabis market. The company has secured purchase orders worth A$5.1 million, with exports planned for late September or early October. This development is expected to enhance Bioxyne’s market positioning in Europe, with future orders potentially exceeding the initial A$5.6 million contract, indicating a strong demand and positive outlook for the company’s operations and stakeholders.
Bioxyne Limited has announced a positive outlook for FY2026, driven by its business expansion in Australia and entry into high-growth markets such as the UK, Germany, and other EU countries. This strategic move is expected to bolster the company’s growth trajectory and enhance its positioning in the pharmaceutical industry, potentially benefiting stakeholders by tapping into new market opportunities.
Bioxyne Limited has announced its FY2026 revenue guidance of $65-75 million and EBITDA guidance of $11.5-13.5 million, driven by growth in its Australian medical cannabis business and international expansion. The company has secured new contracts with large distributors and clinics, including a significant contract in Germany, marking its entry into high-growth markets in the UK, Germany, and other EU countries. This expansion is expected to significantly enhance Bioxyne’s market positioning and contribute to its growth in the coming year.
Bioxyne Limited has released a presentation detailing its FY25 results, emphasizing the importance of understanding the inherent risks and uncertainties associated with forward-looking statements. The company highlights that the information provided is for general purposes and not intended as financial advice or an offer to acquire securities, reflecting a cautious approach to future projections and market conditions.
Bioxyne Limited reported a significant financial turnaround for the year ending June 30, 2025, with a 215% increase in revenue from ordinary activities and a net profit of $4.9 million, compared to a substantial loss in the previous year. This financial improvement highlights Bioxyne’s strengthened market position and operational efficiency, although no dividends were proposed, and the company disposed of a dormant entity, Always Pure Organics Japan KK.
Bioxyne Limited has filed a legal claim against Mr. Ian Owles, a major shareholder, in the Supreme Court of New South Wales. The company alleges that Mr. Owles made misrepresentations leading to the issuance of shares to him, and seeks remedies including the declaration of the shares as void or unenforceable. Bioxyne assures stakeholders that this legal action does not affect its ongoing operations.
Bioxyne Limited has revised its Appendix 4C for the quarter ending 30 June 2025, correcting previous errors in reported cash flow figures. The updated report shows a net cash inflow from operating activities of A$1,554,000 and cash and cash equivalents at the quarter’s end totaling A$7,668,000. This correction provides a clearer picture of the company’s financial health and operational efficiency, potentially impacting stakeholder confidence and market perception positively.
Bioxyne Limited has announced the issuance of 7,000,000 shares at a price of $0.01 per share as part of its Employee Incentive Plan. This move is in compliance with relevant sections of the Corporations Act, and the company confirms there is no ‘excluded information’ to disclose, indicating transparency in its operations.
Bioxyne Limited has announced the issuance of 7,000,000 fully paid ordinary securities, which will be quoted on the ASX. This move is part of an employee incentive scheme and reflects the company’s strategy to enhance its market presence and operational capabilities. The issuance is expected to strengthen Bioxyne’s position in the biotechnology sector, potentially benefiting stakeholders by aligning employee interests with company growth.
Bioxyne Limited has released a presentation containing forward-looking statements regarding its future financial performance and market trends. The company emphasizes that these projections are subject to change due to various risks and uncertainties, and stakeholders should not rely solely on these statements for investment decisions. The presentation is not an offer or solicitation for securities and is intended for informational purposes only.